Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Drug haul : Avon...

    Drug haul : Avon Lifesciences denies any wrongdoings

    Written by savita thakur thakur Published On 19 April 2016 7:41 AM  |  Updated On 19 April 2016 7:41 AM
    Drug haul : Avon Lifesciences denies any wrongdoings

    Mumbai : Pharma company Avon Lifesciences, which has been in news for a massive drug seizure over the weekend, clarified that it has all valid licences and statutory registrations for manufacturing, stocking and selling all products manufactured at its Solapur unit and the products seized are in fact stolen from its premises.


    Last week, in one of the biggest drug hauls in the state, the Thane police had seized 18.5 tonne of banned drug Ephedrine, valued at Rs 2,000 crore, from the Solapur facility of Avon Lifesciences.


    "The company wants to assure all stakeholders that we have all valid licenses and statutory registrations for manufacturing, stocking and sale of all products manufactured at our Solapur site. Also, all the materials have been accounted for and stocked with due notice to statutory authorities concerned.


    "The matter concerned revolves around theft of some material and we are ascertaining the same in active cooperation with the investigating authorities," Avon Lifesciences said in a statement.


    Responding to various media reports about drug seizure at its unit located in Solapur, the company said it is cooperating with the relevant investigating authorities and the FDA to get to the facts around this incident. The company management is cooperating in the matter with the relevant authorities, the release said.


    The company has all relevant licences to manufacture, hold inventory and sale of Ephedrine Hydrochloride and Pseudoephedrine Hydrochloride which are controlled substance and classified under the narcotics category, the company claimed.


    Company sources claimed that the valuation being reported by the cops are too botched up as the market price for a kg of these substances are only Rs 3,800-4,000, making the overall valuation at Rs 7-8 crore and not Rs 2,000 crore.


    The Rs 2,000 crore value quoted in media reports is believed to be street value based on 18,500 kg, subject to the said material being further processed and then sold illegally in drug trade. Ephedrine, by itself, is not an API that can be misused and hence this material that has been seized along with stock at the factory is medicinal and holds zero street value, the company said.

    APIAvon LifesciencesEphedrine HydrochlorideFDAFood and Drug AdministrationPseudoephedrine Hydrochloride
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok